Alkem Laboratories Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 6,277,264 (49%) | — | ₹65,911 Cr |
| NII (HNI) | — | 1,883,179 (15%) | — | ₹19,773 Cr |
| Retail | — | 4,394,086 (34%) | — | ₹46,138 Cr |
| Employee | — | 298,913 (2%) | — | ₹314 Cr |
| Σ Total | — | 12,853,442 (100%) | — | ₹1,349,611 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,700 |
| Retail (Max) | 13 | 182 | ₹191,100 |
| S-HNI (Min) | 14 | 196 | ₹205,800 |
| B-HNI (Min) | 67 | 938 | ₹984,900 |
Financial Statements Amount in ₹ Crore
| Metric | 31 Mar 15 | 31 Mar 14 | 31 Mar 13 |
|---|---|---|---|
| Revenue | 3,360 | 2,840 | 2,469 |
| Profit After Tax | 437 | 440 | 467 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1. To achieve the benefits of listing the Equity Shares on the Stock Exchanges and –
- 2. For the sale of 12,853,442 Equity Shares by the Selling Shareholders. –
Company Overview
Incorporated in 1973, Alkem Labs is leading India based pharmaceutical company engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.
Alkem Labs produces branded generics, generic drugs, active pharmaceutical ingredients and neutraceuticals, which they market in India and 55 countries internationally, primarily the United States.
Company's pharmaceutical business is organized into domestic and international operations. Alkem Labs has a portfolio of over 736 brands in India. Company's most significant therapeutic areas in domestic market are anti-infectives, gastro-intestinal, pain and analgesics, and vitamins, minerals and nutrients.
Alkem Labs have a total of 16 manufacturing facilities: 14 manufacturing facilities at five locations in India and two in the United States. Company have four research and development facilities, two in India and two in the United States. As of June 30, 2015, company employed 483 scientists in research and development functions.
Highlights:
1. Alkem Labs is 5th largest pharmaceutical company in India in terms of domestic sales.
2. Alkem Labs products are also sold in 56 countries. In the United States, company has filed 66 abbreviated new drug applications.
3. Company sells a range of high-quality, cost effective generic drugs to major drug chains, pharmaceutical retailers, wholesalers, food and grocery stores, distributors and managed care companies in the United States.